| Attending joint formulation meetings on pharmaceuticals and special medical materials. | Kanser
> Kanser: çoğu türü | Düzenleyici ortaklık
> Düzenleyici kurumlarla çalışma | 100.000 | National | Sometimes | 119017792133 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance] reimbursement policies for that year. | Kanser
> Kanser: çoğu türü | Düzenleyici ortaklık
> Düzenleyici kurumlarla çalışma | 5.000 | National | Sometimes | 119022421395 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Kanser
> Kanser: çoğu türü | Düzenleyici ortaklık
> Sağlık Teknolojisi Değerlendirmesi (HTA) ve geri ödeme incelemelerine katılın | 5.000 | National | Sometimes | 119022421395 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Nöromüsküler
> Spinal müsküler atrofi (SMA) | Düzenleyici ortaklık
> Sağlık Teknolojisi Değerlendirmesi (HTA) ve geri ödeme incelemelerine katılın | 100 | National | Regularly | 119053648739 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Kanser
> Kanser: çoğu türü | Düzenleyici ortaklık
> Politika yapıcılar/düzenleyicilerle toplantılara katılın/kolaylaştırın | 5.000 | National | Sometimes | 119022421395 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance/Taiwan] reimbursement policies for that year. | Kanser
> Kanser: çoğu türü | Düzenleyici ortaklık
> Politika yapıcılar/düzenleyicilerle toplantılara katılın/kolaylaştırın | 5.000 | National | Sometimes | 119022421395 |
| ... Since 2025, the government [in Taiwan] has also begun implementing its Cancer New Drug Fund policy, and our organisation is recognised as one of 13 patient advocacy groups whose efforts contributed to that successful outcome. | Kanser
> Kanser: çoğu türü | Politika ve mevzuatı etkileme
> Sağlık politikası ve mevzuatını etkileme | 10.000 | National | Sometimes | 119055308347 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Kanser
> Kanser: çoğu türü | Politika ve mevzuatı etkileme
> Kamuoyu dinlemelerine ve istişarelere katılın | 10.000 | National | Sometimes | 119055325391 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Genel sağlık
> Sağlık hizmetleri sunumu | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Adil ilaç fiyatlandırması için savunuculuk yapın | 5.000 | National | Sometimes | 119051396882 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Kanser
> Kanser: meme | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Ürünün geri ödeme listelerine/ulusal formülerlere dahil edilmesi için savunuculuk yapma | 10.000 | National | Regularly | 119016883314 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Genel sağlık
> Sağlık hizmetleri sunumu | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Ürünün geri ödeme listelerine/ulusal formülerlere dahil edilmesi için savunuculuk yapma | 5.000 | National | Sometimes | 119051396882 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Kanser
> Kanser: nöroendokrin (NET) | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Ürünün geri ödeme listelerine/ulusal formülerlere dahil edilmesi için savunuculuk yapma | 100 | National | Sometimes | 119051407743 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Kanser
> Kanser: çoğu türü | Fiyatlandırma ve erişilebilirlik savunuculuğu
> Ürünün geri ödeme listelerine/ulusal formülerlere dahil edilmesi için savunuculuk yapma | 10.000 | National | Sometimes | 119055325391 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Kanser
> Kanser: meme | Erişim yollarının iyileştirilmesi
> İlaçlara/sağlık hizmetlerine eşit erişimi kolaylaştırma | 10.000 | National | Regularly | 119016883314 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Kanser
> Kanser: nöroendokrin (NET) | Erişim yollarının iyileştirilmesi
> İlaçlara/sağlık hizmetlerine eşit erişimi kolaylaştırma | 100 | National | Sometimes | 119051407743 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Nöromüsküler
> Spinal müsküler atrofi (SMA) | Erişim yollarının iyileştirilmesi
> İlaçlara/sağlık hizmetlerine eşit erişimi kolaylaştırma | 100 | National | Regularly | 119053648739 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Kanser
> Kanser: çoğu türü | Erişim yollarının iyileştirilmesi
> İlaçlara/sağlık hizmetlerine eşit erişimi kolaylaştırma | 10.000 | National | Sometimes | 119055308347 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Kanser
> Kanser: çoğu türü | Kanıta dayalı hasta girdisi
> Kararları bilgilendirmek için hasta içgörülerini kullanın | 5.000 | National | Sometimes | 119022421395 |
| We serve as members of the Infected Persons Rights Protection Committee under Taiwan CDC [Centers for Disease Control]. | HIV
> HIV | Kurumsal yönetişim
> Hükümet danışma organlarında temsili sağlayın | 5.000 | National | Regularly | 119021698989 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Kanser
> Kanser: çoğu türü | Kurumsal yönetişim
> Çok paydaşlı ağlar içinde etkin çalışma | 10.000 | National | Sometimes | 119055308347 |
etkileşimler
eylemler & savunuculuk
5 bahsetmeler
